

**PLFSS 2024 (Social Security Finance Bill):  
Leem notes the announcements of the French government,  
and calls for an overhaul of medicines policy**

In a *Les Echos* interview published on 20 September 2023, Industry Minister Roland Lescure sets out the government's medicines cost savings plan and unveils some of the measures contained in the Social Security Finance Bill (PLFSS) for 2024.

Leem notes these announcements, which should help to slow the rapid deterioration in the overall situation of the pharmaceutical industry in France, as objectively reported by the *Observatoire de l'accès des patients aux médicaments et de l'attractivité en France* (Observatory to monitor access to medicines and attractiveness in France) in June this year.

Leem would like to take this opportunity to recognise the quality of dialogue engaged in with the government, and its interest in improving regulatory predictability, especially the commitment given to stabilise the safeguard clause for 2023 and 2024.

It will be paying close attention to ensuring that commitments made by the government are reflected in the forthcoming Social Security Finance Act and are subsequently implemented.

Nevertheless, the regulation planned for 2024 remains at an historically high level. In addition to the €850 million in price cuts - equivalent to the 2023 figure - and a safeguard clause stabilised at €1.6 billion - nothing less than a tax on growth - there are now new savings of €525 million on volumes. On this final point, Leem intends to drive forward proposals and is asking to be closely involved in the future actions of the public authorities alongside all other healthcare sector stakeholders.

*“Over and above these announcements, there is also an urgent need to work with all sector stakeholders on overhauling the medicines policy, based on the findings of the Financing and Regulation of Health Products task force, which recently submitted its conclusions to the Prime Minister, referring to a system that is no longer fit for purpose. This overhaul must address three priorities: access to innovation for all patients, adequate supplies of everyday medicines and enhanced autonomy for French manufacturing”,* says Leem Chairman Thierry Hulot.

---

**Press contacts:**

Stéphanie Bou - +33 (0)1 45 03 88 38 - [sbou@leem.org](mailto:sbou@leem.org) / Virginie Pautre – +33 (0)1 45 03 88 87 – [vpautre@leem.org](mailto:vpautre@leem.org)